Proportion of patients on ART with previous documented HIV drug resistance with VL <50 copies/mL. Record of patients
with three-class virological failure with or without three-class resistance referred/discussed in multidisciplinary team with expert advice. Proportion of patients with TB and CD4 cell count <100 cells/μL started on ART within 2 weeks of starting TB therapy. Proportion of patients with active TB on anti-TB therapy started on ART containing EFV, TDF and FTC. Proportion of patients with HIV and HBV coinfection with CD4 cell counts <500 cells/μL on ART. Proportion of patients with HIV and HBV coinfection starting TDF and FTC as part of their first ART regimen. Proportion of patients with HIV and Selleck Ibrutinib HCV coinfection
and CD4 cell counts <500 cells/μL on ART. Record in patient's selleck chemicals notes of potential pharmacokinetic interactions between ARVs and antiviral hepatitis C agents. Proportion of patients with an AIDS-defining malignancy on ART. Proportion of patients with a non-AIDS-defining malignancy on ART. Record in patient’s notes of potential pharmacokinetic drug interactions between ARVs and systemic anticancer therapy. Proportion of patients with symptomatic HIV-associated NC disorders on ART. Proportion of patients with HIV-associated NC disorders on ART containing two NRTIs and one of the following: NNRTI, or PI/r or INI. Proportion of patients with HIVAN started on ART within 2 weeks of diagnosis of CKD. Number of patients with CKD stages 3–5 on ARVs that are potentially nephrotoxic and record of rationale. Record in patient’s notes of the calculated dose of renally cleared ARVs in patients with CKD stage 3 or greater. Number of patients with high CVD risk on either ABC or FPV/r or LPV/r and record of rationale. Proportion of HIV-positive women with CD4 cell count <350 cells/μL
not on ART. “
“ODIN (once-daily darunavir in treatment-experienced patients) was a 48-week, phase III, randomized, ADAM7 open-label trial comparing once-daily (qd) darunavir/ritonavir (DRV/r) 800/100 mg with twice-daily (bid) DRV/r 600/100 mg, both with an optimized background regimen [OBR; at least two nucleoside reverse transcriptase inhibitors (NRTIs)], in treatment-experienced, HIV-1-infected adults with no DRV resistance-associated mutations (RAMs) at screening. Week 48 analyses of virological response by subgroups are reported. A total of 590 patients were randomized to receive qd (n = 294) or bid (n = 296) DRV/r. Virological response (HIV-1 RNA < 50 copies/mL) was assessed according to: screening HIV-1 RNA (≥ or < 50 000 copies/mL), CD4 cell count, prior protease inhibitor (PI) use, number of active NRTIs in the OBR, presence of mutations (primary PI mutations, PI RAMs or M184V/I), gender, age, race, HIV-1 clade and adherence. Baseline characteristics were well balanced between arms and across subgroups.